search
Back to results

Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines (MEXICHO)

Primary Purpose

Heart Failure

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Metoprolole (Selo-Zok ®)
Placebo
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring SNP, catecholamines, metoprolole, healthy subjects, physiological stress

Eligibility Criteria

18 Years - 30 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Kaukaser
  • Healthy men
  • 18 years < age < 30 years
  • Non-smoker
  • 18 < BMI < 25
  • No chronic diseases
  • Motor-disability that disables completement of cardio-pulmonary exercise-test.

Exclusion Criteria:

  • Alcohol abuse or any other abuse
  • Intake of any narcotic drugs (example: cannabinoids, narcotics, stimulants of central nervous system, hypnotics, hallucinogenes)
  • Any of following medication:

    • astmamedication
    • heartmedication
    • antihistamines
    • antipsycotics
    • NSAIDs
    • rifampicine
    • chinidine
    • glucocorticoids
  • Abnormal ECG, particularly 2. or 3. degree AV-block, sinusbradycardia, sick sinusnode-syndrome, sign of heart failure or ischemia.
  • Allergy or intolerance of metoprolole
  • Lactoseallergy
  • 110 mmHg < Systolic blood pressure < 140 mmHg
  • 60 mmHg < Diastolic blood pressure < 90 mmHg
  • Bloodsucker > 11,1 mmol/L, or fasting, venous bloodsucker >= 7,0 (measured if: 7,8 < BS < 11,1)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    1

    2

    Arm Description

    Metoprolol for 10 days followed by placebo for 7 days.

    Placebo for 7 days followed by Metoprolol for 10 days

    Outcomes

    Primary Outcome Measures

    Changes in stress-triggered response of catecholamines.

    Secondary Outcome Measures

    Change in stress-triggered blood pressure response.
    Change in stress-triggered pulse response.

    Full Information

    First Posted
    April 20, 2009
    Last Updated
    April 21, 2009
    Sponsor
    Rigshospitalet, Denmark
    Collaborators
    Danish Heart Foundation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00885651
    Brief Title
    Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines
    Acronym
    MEXICHO
    Official Title
    A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2009
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 2008 (undefined)
    Primary Completion Date
    August 2009 (Anticipated)
    Study Completion Date
    December 2009 (Anticipated)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Rigshospitalet, Denmark
    Collaborators
    Danish Heart Foundation

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Heart failure is a frequent disease in Denmark, and it is associated with very high mortality. Around 60,000 people in Denmark have heart failure, and there is about 11,000 hospitalizations every year due to this disease. From the time of diagnosis, patients survive an average of 4-5 years. A critical illness mechanism in heart failure is that these patients have high blood levels of catecholamines; epinephrine and norepinephrine, which is stress hormones from the sympathetic nervous system. Standard treatment of heart failure is with the two medical preparations betablockers and ACE-inhibitors. It is not known what effect betablocker-treatment have on blood concentration of epinephrine and norepinephrine. It is the purpose of this study, to investigate the effect of Selo-Zok ® (metoprolol) on the blood concentration of epinephrine and norepinephrine. This is done by creating a stress condition for the body, in this case with the bicycle test, while doing blood samples to determine the concentration of catecholamines. This will be done by 1-week treatment of tablet Selo-Zok ® followed by 1-week treatment of placebo (a substance with no medical effect). Blood samples will be taken to determine small changes in inheritance material (DNA) in the form of point mutations also called single nucleotide polymorphisms, since these changes can affect how we respond to metoprolol treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Heart Failure
    Keywords
    SNP, catecholamines, metoprolole, healthy subjects, physiological stress

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Metoprolol for 10 days followed by placebo for 7 days.
    Arm Title
    2
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo for 7 days followed by Metoprolol for 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    Metoprolole (Selo-Zok ®)
    Intervention Description
    Tablets, 200 mg, once a day, 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Changes in stress-triggered response of catecholamines.
    Time Frame
    2 weeks and 3 days
    Secondary Outcome Measure Information:
    Title
    Change in stress-triggered blood pressure response.
    Time Frame
    2 weeks and 3 days
    Title
    Change in stress-triggered pulse response.
    Time Frame
    2 weeks and 3 days

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    30 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Kaukaser Healthy men 18 years < age < 30 years Non-smoker 18 < BMI < 25 No chronic diseases Motor-disability that disables completement of cardio-pulmonary exercise-test. Exclusion Criteria: Alcohol abuse or any other abuse Intake of any narcotic drugs (example: cannabinoids, narcotics, stimulants of central nervous system, hypnotics, hallucinogenes) Any of following medication: astmamedication heartmedication antihistamines antipsycotics NSAIDs rifampicine chinidine glucocorticoids Abnormal ECG, particularly 2. or 3. degree AV-block, sinusbradycardia, sick sinusnode-syndrome, sign of heart failure or ischemia. Allergy or intolerance of metoprolole Lactoseallergy 110 mmHg < Systolic blood pressure < 140 mmHg 60 mmHg < Diastolic blood pressure < 90 mmHg Bloodsucker > 11,1 mmol/L, or fasting, venous bloodsucker >= 7,0 (measured if: 7,8 < BS < 11,1)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Henrik HP Enghusen Poulsen, MD
    Organizational Affiliation
    Rigshospitalet, Universityhospital of Copenhagen
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    22703382
    Citation
    Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR, Henriksen T, Frandsen E, Forman JL, Torp-Pedersen C, Kober L, Poulsen HE. Effect of the Arg389Gly beta(1)-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol. 2012 Sep;39(9):779-85. doi: 10.1111/j.1440-1681.2012.05736.x.
    Results Reference
    derived

    Learn more about this trial

    Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines

    We'll reach out to this number within 24 hrs